AU2001251165A1 - Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease - Google Patents

Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease

Info

Publication number
AU2001251165A1
AU2001251165A1 AU2001251165A AU5116501A AU2001251165A1 AU 2001251165 A1 AU2001251165 A1 AU 2001251165A1 AU 2001251165 A AU2001251165 A AU 2001251165A AU 5116501 A AU5116501 A AU 5116501A AU 2001251165 A1 AU2001251165 A1 AU 2001251165A1
Authority
AU
Australia
Prior art keywords
compound according
hcv
moiety
hydrogen
protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001251165A
Other languages
English (en)
Inventor
Govinda Rao Bhisetti
John Court
Ethan O'malley
Robert Perni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of AU2001251165A1 publication Critical patent/AU2001251165A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AU2001251165A 2000-04-03 2001-03-29 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease Abandoned AU2001251165A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19456300P 2000-04-03 2000-04-03
US60194563 2000-04-03
US19833000P 2000-04-18 2000-04-18
US60198330 2000-04-18
PCT/US2001/010367 WO2001074768A2 (fr) 2000-04-03 2001-03-29 Inhibiteurs de serine proteases, notamment de la protease ns3 du virus de l'hepatite c

Publications (1)

Publication Number Publication Date
AU2001251165A1 true AU2001251165A1 (en) 2001-10-15

Family

ID=26890159

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001251165A Abandoned AU2001251165A1 (en) 2000-04-03 2001-03-29 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease

Country Status (11)

Country Link
US (1) US7494988B2 (fr)
EP (1) EP1268519B1 (fr)
JP (1) JP4806154B2 (fr)
AT (1) ATE297946T1 (fr)
AU (1) AU2001251165A1 (fr)
CA (1) CA2405043A1 (fr)
DE (1) DE60111509T2 (fr)
ES (1) ES2240446T3 (fr)
IL (2) IL152022A0 (fr)
PT (1) PT1268519E (fr)
WO (1) WO2001074768A2 (fr)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA979327B (en) * 1996-10-18 1998-05-11 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease.
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
HUP0303358A3 (en) 2000-07-21 2005-10-28 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
HU229997B1 (en) * 2000-07-21 2015-04-28 Dendreon Corp San Diego Peptides as ns3-serine protease inhibitors of hepatitis c virus
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP1317450B1 (fr) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Composes de pyrazole utiles comme inhibiteurs de proteine kinase
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
NZ526471A (en) 2000-12-21 2005-08-26 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
CA2434386C (fr) 2001-01-22 2006-12-05 Merck & Co., Inc. Derives de nucleoside servant d'inhibiteurs de l'arn polymerase virale arn dependante
JP2003007697A (ja) * 2001-06-21 2003-01-10 Hitachi Kokusai Electric Inc 半導体装置の製造方法、基板処理方法および基板処理装置
MXPA04000293A (es) 2001-07-11 2004-05-04 Vertex Pharma Inhibidores de serina proteasa biciclica de puente.
EP1441720B8 (fr) 2001-10-24 2012-03-28 Vertex Pharmaceuticals Incorporated Inhibiteurs de la serine protease, en particulier de la protease ns3-ns4a du virus de l'hepatite c, integrant un systeme de cycles accoles
CA2473070C (fr) * 2002-01-23 2009-10-13 Schering Corporation Composes de proline utilises en tant qu'inhibiteurs de la serine protease ns3 dans le traitement d'une infection par le virus de l'hepatite c
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
AU2003223602B8 (en) 2002-04-11 2010-05-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis C virus NS3-NS4 protease
ATE503764T1 (de) * 2002-05-20 2011-04-15 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
TW200510391A (en) * 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
CA2521678A1 (fr) * 2003-04-11 2004-10-28 Vertex Pharmaceuticals, Incorporated Inhibiteurs des serine proteases, en particulier de la protease ns3-ns4a du vhc
AU2011203054B2 (en) * 2003-04-11 2012-04-26 Vertex Pharmaceuticals, Incorporated Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
NZ544076A (en) 2003-05-21 2009-04-30 Boehringer Ingelheim Int Hepatitis C inhibitor compounds
US7109172B2 (en) 2003-07-18 2006-09-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
UY28500A1 (es) * 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
EP1664091A1 (fr) 2003-09-18 2006-06-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de serines proteases, en particulier de la protease ns3-ns4a du vhc
KR20060094083A (ko) 2003-09-22 2006-08-28 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 바이러스에 대해 활성인 마크로사이클릭펩타이드
BRPI0414814A (pt) 2003-09-26 2006-11-14 Schering Corp inibidores macrocìclicos de protease de serina ns3 de vìrus de hepatite c
JP2007532474A (ja) 2003-10-10 2007-11-15 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特にｈｃｖのｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
EP1944042A1 (fr) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinaisons pour le traitement HCV
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
US7253160B2 (en) 2003-11-20 2007-08-07 Schering Corporation Depeptidized inhibitors of hepatitis C virus NS3 protease
AU2004298498B2 (en) 2003-12-11 2008-09-11 Schering Corporation Inhibitors of hepatitis C virus NS3/NS4a serine protease
DE602005025855D1 (de) 2004-01-21 2011-02-24 Boehringer Ingelheim Pharma Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
RS51243B (sr) 2004-01-30 2010-12-31 Medivir Ab. Inhibitori ns-3 serina hcv proteaze
CA2554999A1 (fr) * 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibiteurs de proteases serines, en particulier de la protease hcv ns3-ns4a
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7192957B2 (en) 2004-02-27 2007-03-20 Schering Corporation Compounds as inhibitors of hepatitis C virus NS3 serine protease
ATE478889T1 (de) 2004-02-27 2010-09-15 Schering Corp Neuartige verbindungen als hemmer von hepatitis c-virus ns3-serinprotease
US7816326B2 (en) 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
ATE438622T1 (de) 2004-02-27 2009-08-15 Schering Corp 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
TW200536528A (en) 2004-02-27 2005-11-16 Schering Corp Novel inhibitors of hepatitis C virus NS3 protease
JP2007525521A (ja) * 2004-02-27 2007-09-06 シェーリング　コーポレイション Ｃ型肝炎ウイルスｎｓ３セリンプロテアーゼのインヒビターとしてのシクロブテンジオン基含有化合物
US7635694B2 (en) 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
US8067379B2 (en) 2004-02-27 2011-11-29 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
CN102225936B (zh) * 2004-03-12 2013-09-11 弗特克斯药品有限公司 制备化合物的方法
CA2566610A1 (fr) * 2004-05-20 2005-12-01 Schering Corporation Prolines substituees en tant qu'inhibiteurs de la serine protease du virus ns3 de l'hepatite c
CA2573346C (fr) 2004-07-20 2011-09-20 Boehringer Ingelheim International Gmbh Analogues peptidiques inhibiteurs de l'hepatite c
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
WO2006026352A1 (fr) * 2004-08-27 2006-03-09 Schering Corporation Composes d'acylsulfonamide inhibiteurs de la serine protease ns3 du virus de l'hepatite c
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
EP1924594A2 (fr) * 2005-07-25 2008-05-28 Intermune, Inc. Nouveaux inhibiteurs macrocycliques de la multiplication du virus de l' hépatite c
SI1913015T1 (sl) 2005-07-29 2014-05-30 Janssen R&D Ireland Makrociklični inhibitorji virusa Hepatitis C
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
AR055361A1 (es) 2005-07-29 2007-08-22 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
CA2617679A1 (fr) 2005-08-02 2007-02-08 Steve Lyons Inhibiteurs des serines proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
ATE463480T1 (de) * 2005-08-19 2010-04-15 Vertex Pharma Verfahren und zwischenprodukte
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
WO2007044893A2 (fr) 2005-10-11 2007-04-19 Intermune, Inc. Composés et méthodes pour l'inhibition de la réplication du virus de l'hépatite c
CA2627857A1 (fr) 2005-11-03 2007-05-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines utiles en tant qu'inhibiteurs de kinases
EP1951748B1 (fr) 2005-11-11 2013-07-24 Vertex Pharmaceuticals, Inc. Variantes du virus de l'hépatite c
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
AU2007217355B2 (en) 2006-02-27 2012-06-21 Vertex Pharmaceuticals Incorporated Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
AU2007227544B2 (en) 2006-03-16 2012-11-01 Vertex Pharmaceuticals Incorporated Deuterated hepatitis C protease inhibitors
WO2007120595A2 (fr) * 2006-04-11 2007-10-25 Novartis Ag Composés organiques et leurs utilisations
DE102006059317A1 (de) 2006-07-04 2008-01-10 Evonik Degussa Gmbh Verfahren zur Herstellung von β-Amino-α-hydroxy-carbonsäureamiden
KR20090024834A (ko) 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
EP1886685A1 (fr) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes, utilisations et compositions pour la modulation de la réplication du HCV par activation ou inhibition du récepteur farnesoid X
JP2010519329A (ja) 2007-02-27 2010-06-03 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ阻害剤
TW200846343A (en) 2007-02-27 2008-12-01 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
US8258116B2 (en) 2007-05-04 2012-09-04 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
MX2009012093A (es) * 2007-05-10 2010-01-25 Intermune Inc Nuevos peptidos inhibidores de la replicacion del virus de la hepatitis c.
CA2694499A1 (fr) 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Procede de preparation de la 5-fluoro-1h-pyrazolo[3,4-b]pyridin-3-amine et des derives de celle-ci
US8492546B2 (en) 2007-08-30 2013-07-23 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
GB0718575D0 (en) 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
CA2720729A1 (fr) 2008-04-15 2009-11-26 Intermune, Inc. Nouveaux inhibiteurs macrocycliques de la replication du virus de l'hepatite c
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8980920B2 (en) 2009-05-29 2015-03-17 Merck Sharp & Dohme Corp. Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C
CA2782024A1 (fr) 2009-11-25 2011-06-03 Schering Corporation Composes tricycliques fusionnes et leurs derives utiles pour le traitement de maladies virales
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
JP2013522202A (ja) 2010-03-09 2013-06-13 メルク・シャープ・エンド・ドーム・コーポレイション 縮合三環式シリル化合物およびウイルス疾患の治療のためのその使用方法
JP2013541499A (ja) 2010-07-26 2013-11-14 メルク・シャープ・エンド・ドーム・コーポレイション 置換されたビフェニレン化合物およびウイルス性疾患の治療のためのその使用方法
WO2012050848A1 (fr) 2010-09-29 2012-04-19 Schering Corporation Dérivés tétracycliques condensés et procédés d'utilisation de ceux-ci dans le traitement de maladies virales
EP2635570B1 (fr) 2010-11-01 2017-12-13 RFS Pharma, LLC. Nouveaux inhibiteurs spécifiques de la protéase ns3 du vhc
WO2012107589A1 (fr) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement et la prévention des infections à vhc
EP2696681B1 (fr) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. Dérivés de nucléoside 2'-substitués et procédés d'utilisation de ceux-ci pour le traitement de maladies virales
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (fr) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Composés benzofuranes substitués et leur procédés d'utilisation pour le traitement de maladies virales
WO2013033900A1 (fr) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de maladies virales
WO2013033901A1 (fr) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Dérivés benzofuranes substitués par un hétérocycle et leurs procédés d'utilisation pour le traitement de maladies virales
WO2013039876A1 (fr) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Composés hétérocycliques contenant un silyle et méthodes d'utilisation desdits composés pour traiter les maladies virales
WO2013072328A1 (fr) 2011-11-14 2013-05-23 Sanofi Utilisation de telaprevir et de composés associés pour le traitement de l'athérosclérose, d'une insuffisance cardiaque, de néphropathies, de maladies hépatiques ou de maladies inflammatoires
EP2802574A4 (fr) 2012-01-12 2015-06-24 Rfs Pharma Llc Inhibiteurs de la protéase ns3 du vhc
WO2014053533A1 (fr) 2012-10-05 2014-04-10 Sanofi Utilisation de dérivés substitués de l'acide 3-hétéroaroylamino-propionique en tant que produits pharmaceutiques destinés à la prévention/au traitement de la fibrillation auriculaire
EP3063140A4 (fr) 2013-10-30 2017-11-08 Merck Sharp & Dohme Corp. Pseudopolymorphes d'un inhibiteur de la protéine ns5a du vhc et leurs utilisations
CN117105928B (zh) * 2023-08-22 2024-03-26 上海蓝木化工有限公司 一种蛋白酶抑制剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900238B1 (en) * 1995-12-07 2005-05-31 The Scripps Research Institute HIV protease inhibitors
ZA979327B (en) 1996-10-18 1998-05-11 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease.
ES2281170T3 (es) 1998-03-31 2007-09-16 Vertex Pharmaceuticals Incorporated Inhibidores de serina proteasas, particularmente proteasa ns3 del virus de la hepatitis c.
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
MXPA04000293A (es) 2001-07-11 2004-05-04 Vertex Pharma Inhibidores de serina proteasa biciclica de puente.
EP1441720B8 (fr) 2001-10-24 2012-03-28 Vertex Pharmaceuticals Incorporated Inhibiteurs de la serine protease, en particulier de la protease ns3-ns4a du virus de l'hepatite c, integrant un systeme de cycles accoles
AU2003223602B8 (en) 2002-04-11 2010-05-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis C virus NS3-NS4 protease
CA2521678A1 (fr) 2003-04-11 2004-10-28 Vertex Pharmaceuticals, Incorporated Inhibiteurs des serine proteases, en particulier de la protease ns3-ns4a du vhc
TW200510391A (en) 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7109172B2 (en) 2003-07-18 2006-09-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
UY28500A1 (es) 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
EP1664091A1 (fr) 2003-09-18 2006-06-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de serines proteases, en particulier de la protease ns3-ns4a du vhc
JP2007532474A (ja) 2003-10-10 2007-11-15 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特にｈｃｖのｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
CA2554999A1 (fr) 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibiteurs de proteases serines, en particulier de la protease hcv ns3-ns4a
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c

Also Published As

Publication number Publication date
WO2001074768A2 (fr) 2001-10-11
JP4806154B2 (ja) 2011-11-02
EP1268519A2 (fr) 2003-01-02
PT1268519E (pt) 2005-08-31
ATE297946T1 (de) 2005-07-15
WO2001074768A3 (fr) 2002-06-06
CA2405043A1 (fr) 2001-10-11
EP1268519B1 (fr) 2005-06-15
DE60111509T2 (de) 2006-05-11
US20030236242A1 (en) 2003-12-25
IL152022A (en) 2008-07-08
JP2003529583A (ja) 2003-10-07
ES2240446T3 (es) 2005-10-16
US7494988B2 (en) 2009-02-24
DE60111509D1 (de) 2005-07-21
IL152022A0 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
EP1268519B1 (fr) Inhibiteurs de serine proteases, notamment de la protease ns3 du virus de l'hepatite c
US6608067B1 (en) Inhibitors of serine proteases, particularly HCV NS3 protease
EP0932617B1 (fr) Inhibiteurs de serines proteases, notamment de ns3 protease du virus de l'hepatite c
CN1845920B (zh) 作为丝氨酸蛋白酶、特别是hcvns3-ns4a蛋白酶的抑制剂的2-氨基-4-芳氧基-1-羰基吡咯烷衍生物
RU2412198C2 (ru) Ингибиторы сериновых протеаз, в частности нс3-нс4а протеазы
ES2381548T3 (es) Inhibidores de serina proteasas, particularmente de la proteasa VHC NS3-NS4A
CN101857631A (zh) 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
AU2006202124B2 (en) Inhibitors of Serine Proteases, Particularly Hepatitis C Virus NS3 Protease
CN1906208B (zh) 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
AU719984C (en) Inhibitors of serine proteases, particularly hepatitis c virus NS3 protease